Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma

St. Vincent's Comprehensive Cancer Center, New York

SUNY Health Science Center at Brooklyn, Brooklyn

Western Pennsylvania Cancer Institute, Pittsburgh

Center for Cancer and Blood Disorders, Bethesda

Carolina Hematology-Oncology Associates, Charlotte

Northwest Georgia Oncology Centers, Marietta

Atlanta Cancer Care-Roswell, Roswell

Mayo Clinic, Jacksonville

Cleveland Clinic Myeloma Program Hematology & Medical Oncology /R35, Cleveland

Mayo Clinic, Rochester

Midwest Cancer Research Group, Skokie

Mayo Clinic, Scottsdale

Palo Verde Hematology Oncology, Glendale

Nevada Cancer Center, Las Vegas

Institute for Myeloma and Bone, Los Angeles

Cancer Care Associates, Redondo Beach

Providence St. Joseph Medical Center/Cancer Center, Burbank

Wilshire Oncology Medical Group, Inc., La Verne

Alta Bates Comprehensive Cancer Center, Berkeley

Swedish Cancer Institute, Seattle

Northwestern University Med Ctr, Chicago

University of Maryland Medical Center, Baltimore

Massachusetts General Hospital, Boston

Dana-Farber Cancer Institute, Boston

University of Massachusetts, Worcester

Fred Hutchinson Cancer Research Center, Seattle